Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers
about
Ligand-Independent EGFR SignalingTargeting molecular addictions in cancerErlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domainPotential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastomaGreater than the sum of its parts: single-nucleus sequencing identifies convergent evolution of independent EGFR mutants in GBM.Target validation using chemical probes.Glial progenitors as targets for transformation in glioma.A leak pathway for luminal protons in endosomes drives oncogenic signalling in glioblastomaDevelopment of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.CNS Anticancer Drug Discovery and Development Conference White Paper.InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.Mechanisms of resistance to EGFR targeted therapies.Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.Quantitating cell-cell interaction functions with applications to glioblastoma multiforme cancer cells.An EGFR wild type-EGFRvIII-HB-EGF feed-forward loop regulates the activation of EGFRvIII.EGFR-dependent mechanisms in glioblastoma: towards a better therapeutic strategy.Advances and challenges in the molecular biology and treatment of glioblastoma-is there any hope for the future?Drug-Target Kinetics in Drug Discovery.Occupy EGFR.Identifying Determinants of EGFR-Targeted Therapeutic Biochemical Efficacy Using Computational Modeling.DRR regulates AKT activation to drive brain cancer invasion.A TNF-JNK-Axl-ERK signaling axis mediates primary resistance to EGFR inhibition in glioblastoma.Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.
P2860
Q26797495-370CACEA-50AB-44A1-8FB9-69133A10269CQ26829525-375AAB8A-D0B7-43C0-B9AD-3C5B09039270Q27674725-28EFCB30-5F98-42B6-81C5-9F7E84B88204Q30652283-41E9EFD8-9893-49FC-919D-780AF1E5FE7EQ33923431-DB8AECC7-0878-4EBD-BE5C-8172F0680470Q34333826-FFE47E70-7AA6-4039-999B-0F5E0124F8BDQ34735661-DB47D00D-4FFF-4DB9-8F39-AFC333D0C35AQ35162374-B19CDFA2-3744-4C9E-A465-9F162858CE79Q35612289-9208F4FF-8AB7-4908-9B61-69C1B2B997EAQ36089590-1B243AB0-946B-484E-9B03-743347960E48Q36759183-25ECD3CE-3CD9-4481-8281-B1A998357E80Q36887721-7911CB2F-0956-49C7-9886-41F3FEABBAF3Q36891085-241978EE-B085-4280-A780-BB37B5D7D217Q36923052-79E674B5-EF98-4EF0-B53C-0342952D6280Q37672593-525FF8BE-F3B5-41FF-AF52-DA447E2F28A2Q38199643-E8A8CAD7-6E15-4E3A-B894-5874F88FF725Q38364234-B9051CB3-8458-4862-A731-ABFFA64F8DC8Q39391104-9A44F3F1-7FF1-4D70-AE98-2EBDC3FB5539Q41976220-679761B5-F581-4FDD-801D-8F75D21E513BQ42418384-6789E07D-043A-4288-B7FE-1D398CBCF20FQ45412782-FF23F975-98D3-4558-AEE7-09962638DB4BQ46093038-4005AB52-026A-4F62-8023-778494D9E1EAQ50100856-B38A4817-5253-4C3C-A50A-ED2ADC1AA786
P2860
Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Kinetics of inhibitor cycling ...... -driven lung and brain cancers
@en
Kinetics of inhibitor cycling ...... driven lung and brain cancers.
@nl
type
label
Kinetics of inhibitor cycling ...... -driven lung and brain cancers
@en
Kinetics of inhibitor cycling ...... driven lung and brain cancers.
@nl
prefLabel
Kinetics of inhibitor cycling ...... -driven lung and brain cancers
@en
Kinetics of inhibitor cycling ...... driven lung and brain cancers.
@nl
P2093
P2860
P1433
P1476
Kinetics of inhibitor cycling ...... -driven lung and brain cancers
@en
P2093
Adam L Garske
Jimmy A Blair
Kevan M Shokat
Krister J Barkovich
Qi-Wen Fan
Sujatmi Hariono
P2860
P304
P356
10.1158/2159-8290.CD-11-0287
P577
2012-03-31T00:00:00Z